Get started
Author

Gernot Engstler

Observed names: Engstler Gernot, Engstler, Gernot, G Engstler, G. Engstler
ORCID: 0000-0002-4461-1992
Observed ORCID: 0000-0002-4461-1992
OpenAlex ID: A5036730387
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
2021 · Peter Peneder, Adrian M. Stütz, et al. · Nature Communications · 207
PDF
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
2022 · Edoardo Pennesi, Naomi Michels, et al. · Leukemia · 94
PDF
Action of a silk fabric treated with AEGISTM in children with atopic dermatitis: A 3‐month trial
2007 · D. Y. Koller, G. Halmerbauer, et al. · Pediatric Allergy and Immunology · 61
Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis
2021 · Alicia Baumgartner, Natalia Stepien, et al. · Journal of Personalized Medicine · 37
PDF
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial
2024 · Edoardo Pennesi, Erica Brivio, et al. · Haematologica · 25
PDF
International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects
2024 · Maria Riedmeier, Sonir R R Antonini, et al. · European Journal of Endocrinology · 18
PDF
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study
2023 · Valentino Conter, Maria Grazia Valsecchi, et al. · Journal of Clinical Oncology · 18
PDF
Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms
2021 · Klára Obrová, Silke Grumaz, et al. · American Journal of Hematology · 18
PDF
A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study
2020 · Erica Brivio, Franco Locatelli, et al. · Blood · 16
Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation
2017 · Herbert Pichler, Karolina Horner, et al. · Transplantation and Cellular Therapy · 13
Diagnosis and management of acute appendicitis in 21 pediatric hematology and oncology patients at a tertiary care cancer center
2021 · Hannah von Mersi, Thomas Benkö, et al. · Scientific Reports · 11
PDF
Incidence and Risk Factors of Venous Thromboembolism in Childhood Acute Lymphoblastic Leukaemia – a Population-Based Analysis of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group
2022 · Anna Gidl, Anna Füreder, et al. · Pediatric Hematology and Oncology · 10
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059
2024 · Jen-Hao Wu, Edoardo Pennesi, et al. · Clinical Pharmacokinetics · 8
Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
2024 · Erica Brivio, Edoardo Pennesi, et al. · Blood · 7
PDF
Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial
2026 · Nicolò Peccatori, Franco Locatelli, et al. · The Lancet Haematology · 5
PDF
The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology
2022 · Christina Gradwohl, Gernot Engstler, et al. · Children · 5
PDF
Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports)
2022 · Fiona Poyer, Anna Füreder, et al. · Therapeutic Advances in Hematology · 5
PDF
Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial
2022 · Edoardo Pennesi, Erica Brivio, et al. · Blood · 3
Importance of genetic clarification in cytopenia syndromes (childhood myelodysplastic syndrome forms)
2024 · Wolfgang Novak, Doris Kroiss, et al. · memo - Magazine of European Medical Oncology · 2
PDF
Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study
2024 · Chantal Lucini, Klára Obrová, et al. · Journal of Hematology & Oncology · 2
PDF
Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial
2022 · Edoardo Pennesi, Erica Brivio, et al. · Blood · 2
4CPS-207 Improving the safety of pharmacotherapy in paediatric haemato-oncology by clinical pharmacy services
2022 · C Gradwohl, H Pichler, et al. · European Journal of Hospital Pharmacy · 1
PDF
Sinusoidal obstruction syndrome in children with B‐acute lymphoblastic leukemia (B‐ALL) treated with inotuzumab ozogamicin: Results from the ITCC‐059 trial
2026 · Angela Iannicelli, Franco Locatelli, et al. · HemaSphere
PDF
International Delphi-based consensus: therapeutic approaches for pediatric adrenocortical carcinoma
2026 · Fragoso Maria, Van de Ven Kees, et al. · European Journal of Endocrinology
Incidence and Risk Factors of Symptomatic Osteonecrosis in Children With Acute Lymphoblastic Leukemia—A Population‐Based Analysis of the Austrian ALL‐BFM Study Group
2026 · Katharina Arnold, Leila Ronceray, et al. · eJHaem
Works count: 32
Citation count: 568
H-index: 11
I10-index: 12
Year
Topic
Type